{"DataElement":{"publicId":"7290746","version":"1","preferredName":"Acute Lymphoblastic Leukemia Prior Treatment Regimen Administered Type","preferredDefinition":"A description of the acute lymphoblastic leukemia prior treatment regimen that was administered.","longName":"ALL_PR_TX_REG_ADMIN_TYPE","context":"DCI","contextVersion":"1","DataElementConcept":{"publicId":"7290701","version":"1","preferredName":"Acute Lymphoblastic Leukemia Prior Treatment Regimen Administered","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia._Earlier in time or order._A treatment plan that specifies the dosage, the schedule, and the duration of treatment._The act of having given something (e.g., a medication or test).","longName":"ALL_PR_TX_REG_ADMIN","context":"DCI","contextVersion":"1","ObjectClass":{"publicId":"7290699","version":"1","preferredName":"Acute Lymphoblastic Leukemia Prior Treatment Regimen","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.:Earlier in time or order.:A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","longName":"C3167:C25629:C15697","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A565307F-3A33-37BC-E053-F662850A74C1","latestVersionIndicator":"Yes","beginDate":"2020-05-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-11","modifiedBy":"ONEDATA","dateModified":"2020-05-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCI CRF:  Duke Cancer Institute Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A565307F-3A41-37BC-E053-F662850A74C1","latestVersionIndicator":"Yes","beginDate":"2020-05-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-11","modifiedBy":"KUMMEROA","dateModified":"2020-05-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7290727","version":"1","preferredName":"Acute Lymphoblastic Leukemia Treatment Regimen Type","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia._A treatment plan that specifies the dosage, the schedule, and the duration of treatment._Something distinguishable as an identifiable class based on common qualities.","longName":"ALL_TX_REG_TYP","context":"DCI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other, Specify","valueDescription":"Other","ValueMeaning":{"publicId":"6424136","version":"1","preferredName":"Other","longName":"6424136","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"753441A1-068C-5A23-E053-F662850A6B7A","latestVersionIndicator":"Yes","beginDate":"2018-09-06","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-02-02","changeDescription":null,"administrativeNotes":"2023.2.2 Alt VM added per ticket request CADSR0002006. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A5639C1E-9033-35F3-E053-F662850A529E","beginDate":"2020-05-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-11","modifiedBy":"ONEDATA","dateModified":"2020-05-11","deletedIndicator":"No"},{"value":"Inotuzumab Ozogamicin regimen","valueDescription":"Inotuzumab Ozogamicin Treatment Regimen","ValueMeaning":{"publicId":"7290728","version":"1","preferredName":"Inotuzumab Ozogamicin Treatment Regimen","longName":"7290728","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.: A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A5639C1E-9040-35F3-E053-F662850A529E","latestVersionIndicator":"Yes","beginDate":"2020-05-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-11","modifiedBy":"ONEDATA","dateModified":"2020-05-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A5639C1E-9059-35F3-E053-F662850A529E","beginDate":"2020-05-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-11","modifiedBy":"ONEDATA","dateModified":"2020-05-11","deletedIndicator":"No"},{"value":"PEG-asparaginase regimen","valueDescription":"Pegaspargase Treatment Regimen","ValueMeaning":{"publicId":"7290729","version":"1","preferredName":"Pegaspargase Treatment Regimen","longName":"7290729","preferredDefinition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04): A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegaspargase","conceptCode":"C1200","definition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A5639C1E-9066-35F3-E053-F662850A529E","latestVersionIndicator":"Yes","beginDate":"2020-05-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-11","modifiedBy":"ONEDATA","dateModified":"2020-05-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A5639C1E-907F-35F3-E053-F662850A529E","beginDate":"2020-05-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-11","modifiedBy":"ONEDATA","dateModified":"2020-05-11","deletedIndicator":"No"},{"value":"Hyper-CVAD regimen","valueDescription":"HyperCVAD Regimen","ValueMeaning":{"publicId":"6002978","version":"1","preferredName":"HyperCVAD Regimen","longName":"6002978","preferredDefinition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule, used to treat adult L3 acute lymphoblastic leukemia (ALL3 or Burkitt's-type) and adult small non-cleaved cell (Burkitt's) lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HyperCVAD Regimen","conceptCode":"C63455","definition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule that is used to treat adult acute lymphoblastic leukemia (ALL) or Burkitt-type ALL and adult small non-cleaved cell (Burkitt) lymphoma, AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN) and T-cell lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F089D-FFC0-475C-E053-F662850A6912","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A5639C1E-9093-35F3-E053-F662850A529E","beginDate":"2020-05-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-11","modifiedBy":"ONEDATA","dateModified":"2020-05-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7290726","version":"1","preferredName":"Acute Lymphoblastic Leukemia Treatment Regimen Type","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.:A treatment plan that specifies the dosage, the schedule, and the duration of treatment.:Something distinguishable as an identifiable class based on common qualities.","longName":"C3167:C15697:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A5639C1E-900F-35F3-E053-F662850A529E","latestVersionIndicator":"Yes","beginDate":"2020-05-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-11","modifiedBy":"ONEDATA","dateModified":"2020-05-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCI CRF:  Duke Cancer Institute Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A5639C1E-9020-35F3-E053-F662850A529E","latestVersionIndicator":"Yes","beginDate":"2020-05-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-11","modifiedBy":"KUMMEROA","dateModified":"2020-05-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Acute Lymphoblastic Leukemia","type":"Preferred Question Text","description":"Acute Lymphoblastic Leukemia Treatment Prior Regimen Type","url":null,"context":"DCI"}],"origin":"DCI CRF:  Duke Cancer Institute Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A5649DAE-FCEC-3C68-E053-F662850A9DC3","latestVersionIndicator":"Yes","beginDate":"2020-05-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-11","modifiedBy":"KUMMEROA","dateModified":"2020-05-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}